How much has Akeso received from Summit?
By June 30, 2026, Summit had paid Akeso $515 million in cumulative upfront consideration under Akeso’s original ivonescimab license and its 2024 territory expansion, including cash and shares. The July 23, 2026 filing also disclosed up to $4.555 billion in potential regulatory and sales milestones; those conditional amounts should not be counted as money already received.
| Measure | Reported result | Basis |
|---|---|---|
| Original upfront consideration | $500 million | Paid; includes cash and shares |
| 2024 expansion upfront | $15 million | Paid for additional territories |
| Cumulative upfront consideration | $515 million | Original plus expansion; not all cash |
| Potential remaining milestones | Up to $4.555 billion | Conditional regulatory and sales milestones |
Ivonescimab after the FDA letter
On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received an FDA complete response letter for Akeso’s ivonescimab. In the 438-patient HARMONi trial, primary overall survival yielded p=0.057 against a prespecified threshold of 0.0448; median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. The application could not be approved on the current data. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.
Sources
Read the full analysis
FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026